Explore more
News
Sarepta Says Another Patient Died
Digest more
Sarepta Therapeutics, Inc. faces setbacks with Elevidys, safety issues, and workforce cuts, raising concerns about its ...
Sarepta Therapeutics appears to have right-sized itself after laying off over a third of its staff, announcing a significant ...
The company aims to focus on high-impact programmes to meet its 2027 financial obligations and support long-term viability.
Just how many employees is Sarepta Therapeutics laying off? And why did the FDA reject Ultragenyx's rare disease drug over ...
The favorable market reaction indicates investor relief at management’s swift measures to rectify the company's worsening ...
Sarepta's cost-saving moves, FDA surprises, and pipeline potential position SRPT as a unique opportunity. Read here for an ...
Shares of drug developer Sarepta Therapeutics surged more than 20% in morning trading, rising after the late-Wednesday news ...
The pharma company said it would lay off a third of its workforce and add a black-box warning to its controversial gene ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback